Sglt-2 Inhibitors, an Issue of Heart Failure Clinics

Volume 18-4
Erscheinungsjahr 2022
ISBN: 978-0-323-96046-5
Verlag: Elsevier Health Sciences

Buch, Englisch, 240 Seiten, Format (B × H): 178 mm x 257 mm, Gewicht: 544 g

In this issue, guest editors bring their considerable expertise to this important topic.

Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

Autoren/Hrsg.

Bhatt, Deepak L

Baliga, Ragavendra R

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Kardiologie, Angiologie, Phlebologie

Inhaltsverzeichnis

Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
Renoprotective Effects of SGLT2 Inhibitors
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection
SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits
Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease
SGLT2 Inhibitors and Safety in Older Patients
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

Über Autor(innen)

Bhatt, Deepak L
Deepak L. Bhatt, MD, MPH, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. A leading authority internationally on interventional cardiology in addition